Tata India Pharma & Healthcare Fund
NAV
₹37.99
as of 6 Oct 2026
Tata India Pharma & Healthcare Fund is an open-ended Sectoral/ Thematic scheme from Tata Mutual Fund managing ₹1,565 crore (as of 31 Aug 2026). Its Direct-plan NAV is ₹37.99 as of 6 Oct 2026. The expense ratio is 1% a year. Managed by Rajat Srivastava. This page is factual data only – it carries no rating and no recommendation.
Key facts
- Expense ratio
- 1% / yr
- as of 31 Aug 2026
- Fund size
- ₹1,565 crore
- as of 31 Aug 2026
- Exit load
- 0.25%
- SIP available
- Yes
- Launched
- 28 Dec 2015
- ISIN
- INF277K019A3
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from nyvo’s own NAV data.
Rebased to 100data to 5 Oct 2026Benchmark: Nifty 500 Healthcare TRI
Tata India Pharma & Healthcare Fund
₹192
+92% on ₹100 over 5.0 yrs
Sectoral/ Thematic average
₹198
+98% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | -2.22% | -4.47% | +2.25 |
| 6 months | 12.18% | 7.56% | +4.62 |
| 1 year | 6.06% | -0.10% | +6.16 |
| 3 years (CAGR) | 18.53% | 12.32% | +6.21 |
| 5 years (CAGR) | 13.60% | 11.84% | +1.76 |
Category average across 119 funds, as of 5 Oct 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible – read that number first.
1-year holding periods
- Worst
- -6.8%
- Median
- 13.5%
- Best
- 61.5%
49 windows over the last 60 months, stepped monthly; 82% ended positive. Worst window began 3 Jan 2022. Windows overlap – this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 18.5%
- Median
- 23.0%
- Best
- 26.5%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 3 Oct 2023. Windows overlap – this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.89
- Sharpe ratio (5Y)
- 0.60
- Sortino ratio (3Y)
- 1.49 vs category 1.63
- Standard deviation (3Y)
- 16.38%
- Beta (3Y)
- 0.99
- Alpha (3Y)
- -1.03%
- Deepest fall (5Y)
- -16.17%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high – how deep and for how long is what a drawdown feels like.
Deepest fall
-16.2%
Right now
-6.2% below peak
Ahead of its benchmark in 50% of months (window: 3y, monthly) – benchmark: Nifty 500 Healthcare TRI, name shown only.
Where the money actually is
Equity
99.5%
Cash
0.5%
Whole-portfolio split, as of 31 Aug 2026.
What it owns
43 positions · top 10 = 50.2%
Market-cap mix
Large 23.3%Mid 36.1%Small 37.3%Other 3.2%
as of 31 Aug 2026
Holdings by sector
Healthcare(10 in top 10)90.9%
- Sun Pharmaceuticals Industries Ltd8.43%
- HealthCare Global Enterprises Ltd6.30%
- Divi's Laboratories Ltd5.65%
- Abbott India Ltd5.44%
- Rainbow Childrens Medicare Ltd4.47%
- Apollo Hospitals Enterprise Ltd4.32%
- Cipla Ltd4.27%
- Dr Reddy's Laboratories Ltd4.21%
- Max Healthcare Institute Ltd Ordinary Shares3.80%
- Fortis Healthcare Ltd3.30%
- Basic Materials7.0%
- Consumer Defensive1.1%
- Financial Services0.5%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Aug 2026. Portfolio turnover 65.0% vs category 37.4% a year.
The businesses it owns
- P/E (trailing)
- 40.6 vs category 25.9
- P/B
- 6.3 vs category 3.9
- Dividend yield
- 0.9% vs category 1.1%
- Net margin
- 15.7% vs category 15.4%
- Earnings growth
- 16.1%
- Avg market cap
- ₹52,140 crore
Money in, money out
- Net flow, 12 months
- +₹100 cr
- Net flow, 3 months
- +₹59 cr
as of 31 Aug 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of Tata India Pharma & Healthcare Fund?
- ₹37.99 per unit as of 6 Oct 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of Tata India Pharma & Healthcare Fund?
- 1% a year for the Direct plan, as of 31 Aug 2026.
- How large is Tata India Pharma & Healthcare Fund?
- ₹1,565 crore under management as of 31 Aug 2026, in the Sectoral/ Thematic category.
- How risky is Tata India Pharma & Healthcare Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of Tata India Pharma & Healthcare Fund?
- 13.60% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 11.84%. Past returns do not predict future returns.
- What is the worst 3-year return of Tata India Pharma & Healthcare Fund?
- 18.5% a year – the weakest of 25 overlapping 3-year holding periods, beginning 3 Oct 2023. The median was 23.0% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages Tata India Pharma & Healthcare Fund?
- Rajat Srivastava, managing this fund for 2 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund – growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,338 crore
- ICICI Prudential Business Cycle Fund₹15,873 crore
- Tata Digital India Fund₹10,322 crore
- Tata Ethical Fund₹3,861 crore
- quant Quantamental Fund₹1,642 crore
- Aditya Birla Sun Life Conglomerate Fund₹1,610 crore
- Kotak Banking and Financial Services Fund₹1,561 crore
- ICICI Prudential FMCG Fund₹1,557 crore
Data: nyvo research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.